Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Policy & Regulation
Trends & Finance
Financial Results: Page 3
Myriad Genetics Q4 revenues rise 11% on strength in hereditary cancer, pharmacogenomics testing
By
LabPulse.com staff writers
Revenue for the quarter ended December 31 was driven by 16% growth in hereditary cancer testing volumes and 23% growth in volumes for the GeneSight pharmacogenomics test.
March 1, 2023
Agilent Technologies Q1 revenues rise 5% on strength in life sciences, applied markets
February 28, 2023
Opko Health Q4 revenues drop 54% as BioReference business reduces costs
By
LabPulse.com staff writers
BioReference processed approximately 100,000 COVID-19 PCR tests in the fourth quarter of 2022 compared with 2.7 million tests in the fourth quarter of 2021.
February 24, 2023
Guardant Health shares rise on Q4 growth in clinical, biopharma testing
By
Leo O'Connor
For Q4, the firm reported 36,000 tests to clinical customers and 8,200 tests to biopharmaceutical customers, representing an increase of 41% and 24%, respectively, over the fourth quarter of 2021.
February 24, 2023
Labcorp Q4 revenues drop 10% despite base business growth
By
LabPulse.com staff writers
The firm booked $1.1 billion in 2022 revenue for COVID-19 testing, but it expects such revenue to drop by 75% to 90% in 2023.
February 16, 2023
QuidelOrtho anticipates $2.8B to $3.1B in 2023 revenue, sees COVID-19 as another seasonal virus
By
Leo O'Connor
The firm is seeing greater access to semiconductor chips and expects inflation and supply chain challenges to further ease as this year progresses, said its CFO Joseph Busky.
February 16, 2023
Q4 revenue rose 94%, but OraSure to eliminate 'non-production' roles in restructuring
By
Leo O'Connor
The restructuring is expected to impact 11% of its non-production workforce and with other savings, yield annual operating expense reductions of approximately $15 million.
February 15, 2023
As Qiagen Q4 net sales declined 14%, base business sales grew double digits
By
Leo O'Connor
The firm saw a 15% year-over-year sales increase for non-COVID-19 products, due to strong growth in sales of consumables and related products as well as instruments.
February 8, 2023
Quest Diagnostics Q4 revenues down 15% on COVID testing but base business grew
By
LabPulse.com staff writers
Fourth-quarter COVID-19 testing revenues of $184 million dropped 75% compared to 2021, but base business revenues, excluding COVID sales, rose 6% year-over-year to $2.15 billion.
February 2, 2023
Hologic fiscal Q1 diagnostics revenues drop 27% on lower demand for COVID testing
By
Leo O'Connor
Stephen MacMillan, Hologic chairman, president, and CEO, said he believes that the firm is well positioned for long-term growth while COVID testing declines.
February 2, 2023
Roche reports flat diagnostics revenue growth for 2022
By
Leo O'Connor
For COVID-19 tests, Roche booked 2022 revenues of 4.1 billion Swiss francs, down 13% compared to 4.7 billion Swiss francs in 2021. Revenue growth for its base diagnostics business offset the decline.
February 2, 2023
Abbott CEO expects high single-digit sales growth excluding COVID-19 revenues in 2023
By
Leo O'Connor
The firm booked diagnostics segment revenues of $3.31 billion in the fourth quarter, down 26.1% year over year. Nonetheless, its CEO sees some easing of macroenvironment challenges that impacted growth in 2022.
January 25, 2023
Previous Page
Page 3 of 12
Next Page